Vivos Therapeutics, Inc.
VVOS
$4.20
-$0.40-8.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.39M | 14.63M | 15.03M | 14.58M | 14.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.39M | 14.63M | 15.03M | 14.58M | 14.02M |
| Cost of Revenue | 6.34M | 6.04M | 6.01M | 5.57M | 5.60M |
| Gross Profit | 8.05M | 8.59M | 9.02M | 9.01M | 8.42M |
| SG&A Expenses | 21.51M | 19.28M | 19.61M | 20.92M | 21.33M |
| Depreciation & Amortization | 773.00K | 612.00K | 581.00K | 586.00K | 590.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.63M | 25.93M | 26.20M | 27.08M | 27.52M |
| Operating Income | -14.23M | -11.31M | -11.17M | -12.50M | -13.49M |
| Income Before Tax | -14.32M | -11.24M | -11.14M | -12.57M | -12.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.32 | -11.24 | -11.14 | -12.57 | -12.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.32M | -11.24M | -11.14M | -12.57M | -12.05M |
| EBIT | -14.23M | -11.31M | -11.17M | -12.50M | -13.49M |
| EBITDA | -13.46M | -10.69M | -10.59M | -11.91M | -12.91M |
| EPS Basic | -2.00 | -2.05 | -3.23 | -5.84 | -6.98 |
| Normalized Basic EPS | -1.25 | -1.28 | -2.02 | -3.65 | -4.36 |
| EPS Diluted | -2.00 | -2.05 | -3.23 | -5.84 | -6.98 |
| Normalized Diluted EPS | -1.25 | -1.28 | -2.02 | -3.65 | -4.36 |
| Average Basic Shares Outstanding | 29.20M | 23.34M | 17.05M | 11.24M | 8.15M |
| Average Diluted Shares Outstanding | 29.20M | 23.34M | 17.05M | 11.24M | 8.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |